Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bevacizumab-induced Invasion in U87 Glioma

Bevacizumab (BEV) is an antiangiogenic drug approved for glioblastoma (GBM) treatment. However, it does not increase survival and is associated with glioma invasion. Angiostatin is an antiangiogenic polypeptide that also inhibits migration of cancer cells, but is difficult to deliver. Oncolytic viru...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Zhang, Wei, Fulci, Giulia, Buhrman, Jason S, Stemmer-Rachamimov, Anat O, Chen, John W, Wojtkiewicz, Gregory R, Weissleder, Ralph, Rabkin, Samuel D, Martuza, Robert L
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group 2012
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3255598/
https://ncbi.nlm.nih.gov/pubmed/21915104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.187
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन